Waymo is a bright spot in the Google story, says Truist's Youssef Squali
Youssef Squali, Truist Global head of internet and media, joins 'Squawk on the Street' to discuss Alphabet post earnings.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Intuitive Surgical analyst raises eyebrows with new stock price target
Intuitive Surgical analyst raises eyebrows with new stock price target originally appeared on TheStreet. Jim Cramer wants answers. The CNBC anchor and Mad Money maven wants to know why Deutsche Bank was being so rough on Intuitive Surgical () . The investment firm downgraded the biotech to sell from hold and slashed its stock price target to $440 from $515. 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰 "This is quite a controversial call," Cramer said on CNBC's Squawk on The Street, "because this is a premier fast-growing company, premier super growth, and I want to find out more about it." The Sunnyvale, Calif., company, founded in 1995, specializes in robotic-assisted surgery equipment, most notably the Da Vinci surgical systems, which use a minimally invasive approach. Intuitive Surgical's shares were down 6.1% at last check but are up 25.4% from a year ago. Deutsche Bank said in a note to investors on June 9 that remanufactured instruments are going to increasingly encroach on Intuitive's instruments and accessories segment over the next few years. The investment firm expects a growing number of Intuitive's customers to explore adopting remanufactured instruments, given potentially significant profitability gains. The firm cited its discussions with multiple robotic surgery programs. Remanufactured instruments are previously used surgical instruments that have been rigorously overhauled. More Tech Stocks: Palantir gets great news from the Pentagon Analyst has blunt words on Trump's iPhone tariff plans OpenAI teams up with legendary Apple exec Deutsche Bank says 46% of Intuitive's U.S. instruments and accessories revenue could be at risk of encroachment by third-party-remanufactured devices. The firm's model assumes no material impact in 2026 but steadily increasing headwinds in 2027 and especially 2028. Cramer begged to differ. "This is a pristine company and people who know this company have been rewarded repeatedly by owning it," he said. Just a few days earlier, on June 5, Erste Group analyst Hans Engel upgraded Intuitive Surgical to buy from hold, according to The Fly. The company's operating margin should widen again in 2026 and profit growth should increase significantly, the analyst said. Engel said that he expected the share price to rise further due to Intuitive's expected acceleration in growth. On April 2 Intuitive Surgical beat Wall Street's first-quarter earnings and revenue expectations, with sales increasing 19% from a year ago to $2.25 billion. "Our business performed well in the first quarter of the year with physicians using our products at the high end of our expectations, driven by strong procedure growth in core general surgery in the United States, and strong procedures outside the United States," CEO Gary Guthart told analysts. "New system placements in the quarter were solid with particular strength in the U.S." First-quarter 2025 instruments and accessories revenue increased 18% from a year earlier to $1.37 billion, driven primarily by roughly 17% growth in da Vinci procedure volume and about 58% volume growth in the Ion procedure, which gives doctors a nonsurgical way to biopsy lung nodules."Mad Money" marked its 20th anniversary this year and Cramer, who co-founded TheStreet in 1996, said Intuitive Surgical was the eighth best performer of the 'Mad Money era.' "This is another name that we found early on," he said. "I first interviewed someone from the company back in July of 2005 when the stock was trading at a split-adjusted price of $5 and change." He added that the company was now a '$184 billion behemoth, and this stock has given you more than 10,000% gain since the show got started." "I think this is as relevant as ever," Cramer said. "I'm proud to be a huge supporter of this.' The company recently said that effective July 1, Guthart would become executive chairman while Dave Rosa, currently president, would become CEO. On May 22, Citi raised its price target on Intuitive Surgical to $650 from $590 and kept a buy rating on the shares. The firm updated models in medical technology following the Q1 reports. Underlying fundamentals in the sector appear intact, including volumes, pricing, and capital spending, the investment firm said. In March, The Robot Report said that while Intuitive Surgical. remains the leading surgical robotics provider 'other companies with savvy strategies are generating buzz and raising money.' The report listed several companies, including Medtronic () , Stryker () and CMR Surgical, which reportedly has brought in advisers to explore a potential Surgical analyst raises eyebrows with new stock price target first appeared on TheStreet on Jun 9, 2025 This story was originally reported by TheStreet on Jun 9, 2025, where it first appeared.
Miami Herald
9 hours ago
- Miami Herald
Intuitive Surgical analyst raises eyebrows with new stock price target
Jim Cramer wants answers. The CNBC anchor and Mad Money maven wants to know why Deutsche Bank was being so rough on Intuitive Surgical (ISRG) . The investment firm downgraded the biotech to sell from hold and slashed its stock price target to $440 from $515. Don't miss the move: Subscribe to TheStreet's free daily newsletter "This is quite a controversial call," Cramer said on CNBC's Squawk on The Street, "because this is a premier fast-growing company, premier super growth, and I want to find out more about it." The Sunnyvale, Calif., company, founded in 1995, specializes in robotic-assisted surgery equipment, most notably the Da Vinci surgical systems, which use a minimally invasive approach. Intuitive Surgical's shares were down 6.1% at last check but are up 25.4% from a year ago. Deutsche Bank said in a note to investors on June 9 that remanufactured instruments are going to increasingly encroach on Intuitive's instruments and accessories segment over the next few years. The investment firm expects a growing number of Intuitive's customers to explore adopting remanufactured instruments, given potentially significant profitability gains. The firm cited its discussions with multiple robotic surgery programs. Remanufactured instruments are previously used surgical instruments that have been rigorously overhauled. More Tech Stocks: Palantir gets great news from the PentagonAnalyst has blunt words on Trump's iPhone tariff plansOpenAI teams up with legendary Apple exec Deutsche Bank says 46% of Intuitive's U.S. instruments and accessories revenue could be at risk of encroachment by third-party-remanufactured devices. The firm's model assumes no material impact in 2026 but steadily increasing headwinds in 2027 and especially 2028. Cramer begged to differ. "This is a pristine company and people who know this company have been rewarded repeatedly by owning it," he said. Just a few days earlier, on June 5, Erste Group analyst Hans Engel upgraded Intuitive Surgical to buy from hold, according to The Fly. The company's operating margin should widen again in 2026 and profit growth should increase significantly, the analyst said. Engel said that he expected the share price to rise further due to Intuitive's expected acceleration in growth. On April 2 Intuitive Surgical beat Wall Street's first-quarter earnings and revenue expectations, with sales increasing 19% from a year ago to $2.25 billion. "Our business performed well in the first quarter of the year with physicians using our products at the high end of our expectations, driven by strong procedure growth in core general surgery in the United States, and strong procedures outside the United States," CEO Gary Guthart told analysts. "New system placements in the quarter were solid with particular strength in the U.S." First-quarter 2025 instruments and accessories revenue increased 18% from a year earlier to $1.37 billion, driven primarily by roughly 17% growth in da Vinci procedure volume and about 58% volume growth in the Ion procedure, which gives doctors a nonsurgical way to biopsy lung nodules. Related: Analysts reboot Intuitive Surgical stock price target ahead of earnings "Mad Money" marked its 20th anniversary this year and Cramer, who co-founded TheStreet in 1996, said Intuitive Surgical was the eighth best performer of the "Mad Money era." "This is another name that we found early on," he said. "I first interviewed someone from the company back in July of 2005 when the stock was trading at a split-adjusted price of $5 and change." He added that the company was now a "$184 billion behemoth, and this stock has given you more than 10,000% gain since the show got started." "I think this is as relevant as ever," Cramer said. "I'm proud to be a huge supporter of this." The company recently said that effective July 1, Guthart would become executive chairman while Dave Rosa, currently president, would become CEO. On May 22, Citi raised its price target on Intuitive Surgical to $650 from $590 and kept a buy rating on the shares. The firm updated models in medical technology following the Q1 reports. Underlying fundamentals in the sector appear intact, including volumes, pricing, and capital spending, the investment firm said. In March, The Robot Report said that while Intuitive Surgical. remains the leading surgical robotics provider "other companies with savvy strategies are generating buzz and raising money." The report listed several companies, including Medtronic (MDT) , Stryker (SYK) and CMR Surgical, which reportedly has brought in advisers to explore a potential sale. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
10 hours ago
- Yahoo
WPP Media cuts 2025 global advertising revenue growth forecast to 6% on trade concerns
(Reuters) -Global advertising revenue is expected to grow 6% this year, WPP Media said on Monday, lowering its earlier target of 7.7% due to uncertainty over U.S. trade policies. Advertisers are appearing to delay making new commitments to their marketing plans because of the shifting policies, according to a report by the media investment arm of ad group WPP . WHY IT'S IMPORTANT Digital ad spending by companies is a major driver of revenue for Alphabet-owned search giant Google and social media firms such as Meta Platforms, Pinterest, Reddit and Snap. Economic uncertainty is accelerating the adoption of AI tools in ad production and targeting, the WPP Media report said. Meta aims to allow brands to fully create and target ads with its AI tools by the end of 2026, the Wall Street Journal reported last week. Research firm Emarketer recently said companies that rely on traditional keyword-based search ads could lose revenue due to the growing popularity of AI-driven search ads. BY THE NUMBERS WPP Media now expects global ad revenue to reach $1.08 trillion in 2025, with 6.1% growth projected for 2026. Digital advertising is expected to account for 73.2% of the global revenue this year. In 2025, user-generated content will account for a greater share of ad revenue than professionally produced content, the report said. It forecast print advertising revenue will fall 3.1% to $45.5 billion this year, while search revenue is expected to grow 7.3%. CONTEXT WPP Media said brands are expected to prioritize flexible ad contracts, shift budgets toward media placements that reach consumers directly and focus on secure data strategies amid economic uncertainty. The U.S. remains the largest ad market and is expected to grow 5.6% to $404.7 billion, followed by China and the UK, according to the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
